CA2839398A1 - Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders - Google Patents
Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders Download PDFInfo
- Publication number
- CA2839398A1 CA2839398A1 CA2839398A CA2839398A CA2839398A1 CA 2839398 A1 CA2839398 A1 CA 2839398A1 CA 2839398 A CA2839398 A CA 2839398A CA 2839398 A CA2839398 A CA 2839398A CA 2839398 A1 CA2839398 A1 CA 2839398A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mol
- treatment
- cndot
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CGWXYEIWDQDFIU-UHFFFAOYSA-N CC(C)C1C(C)CCC1 Chemical compound CC(C)C1C(C)CCC1 CGWXYEIWDQDFIU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502656P | 2011-06-29 | 2011-06-29 | |
| US61/502,656 | 2011-06-29 | ||
| PCT/GB2012/051503 WO2013001294A1 (en) | 2011-06-29 | 2012-06-27 | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2839398A1 true CA2839398A1 (en) | 2013-01-03 |
Family
ID=46420454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2839398A Abandoned CA2839398A1 (en) | 2011-06-29 | 2012-06-27 | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
Country Status (16)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017161518A1 (en) | 2016-03-23 | 2017-09-28 | Astrazeneca Ab | New physical form |
| CN108314670B (zh) * | 2018-02-06 | 2020-04-07 | 江苏八巨药业有限公司 | 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法 |
| EP4253396A4 (en) * | 2020-11-27 | 2024-09-11 | Mirailab Bioscience Inc. | HIGH PURITY BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) AND PROCESS FOR ITS PRODUCTION |
| CN116283781B (zh) * | 2022-12-16 | 2025-05-13 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途 |
| KR102571432B1 (ko) * | 2023-02-08 | 2023-08-29 | 주식회사 에스씨엘테라퓨틱스 | 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| GB0315509D0 (en) | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| KR20130090877A (ko) | 2010-07-21 | 2013-08-14 | 아스트라제네카 아베 | 흡입기 |
| CN103118727B (zh) | 2010-07-21 | 2015-11-25 | 阿斯利康(瑞典)有限公司 | 吸入器 |
-
2012
- 2012-06-27 IN IN23MUN2014 patent/IN2014MN00023A/en unknown
- 2012-06-27 WO PCT/GB2012/051503 patent/WO2013001294A1/en active Application Filing
- 2012-06-27 KR KR1020137033086A patent/KR20140036230A/ko not_active Withdrawn
- 2012-06-27 MX MX2013014566A patent/MX2013014566A/es not_active Application Discontinuation
- 2012-06-27 SG SG2013089966A patent/SG195309A1/en unknown
- 2012-06-27 EP EP12731150.4A patent/EP2726464A1/en not_active Withdrawn
- 2012-06-27 RU RU2013153466/04A patent/RU2013153466A/ru not_active Application Discontinuation
- 2012-06-27 BR BR112013031759A patent/BR112013031759A2/pt not_active IP Right Cessation
- 2012-06-27 CA CA2839398A patent/CA2839398A1/en not_active Abandoned
- 2012-06-27 JP JP2014517935A patent/JP2014527955A/ja active Pending
- 2012-06-27 AU AU2012277514A patent/AU2012277514A1/en not_active Abandoned
- 2012-06-27 CN CN201280039142.8A patent/CN103814015A/zh active Pending
- 2012-06-28 UY UY0001034170A patent/UY34170A/es not_active Application Discontinuation
- 2012-06-28 TW TW101123228A patent/TW201305115A/zh unknown
- 2012-06-29 AR ARP120102359A patent/AR086818A1/es unknown
-
2013
- 2013-12-13 ZA ZA2013/09480A patent/ZA201309480B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG195309A1 (en) | 2013-12-30 |
| AR086818A1 (es) | 2014-01-22 |
| RU2013153466A (ru) | 2015-08-10 |
| CN103814015A (zh) | 2014-05-21 |
| BR112013031759A2 (pt) | 2016-12-13 |
| UY34170A (es) | 2013-01-31 |
| JP2014527955A (ja) | 2014-10-23 |
| TW201305115A (zh) | 2013-02-01 |
| IN2014MN00023A (enrdf_load_stackoverflow) | 2015-06-12 |
| KR20140036230A (ko) | 2014-03-25 |
| WO2013001294A1 (en) | 2013-01-03 |
| AU2012277514A1 (en) | 2014-01-09 |
| EP2726464A1 (en) | 2014-05-07 |
| MX2013014566A (es) | 2014-09-25 |
| ZA201309480B (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2291369B1 (en) | Benzodioxinyl substituted indazole derivatives | |
| US7960551B2 (en) | Compound | |
| KR20050047552A (ko) | 베타-2 작용제로서의 인돌 유도체 | |
| CA3086747A1 (en) | Compounds | |
| JP7153030B2 (ja) | オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法 | |
| TWI391391B (zh) | 多晶型 | |
| CA2839398A1 (en) | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders | |
| CA3170664A1 (en) | P2x3 modulators | |
| WO2011110852A1 (en) | Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide | |
| TW201204411A (en) | Alkaloid aminoester derivatives and medicinal compositions thereof | |
| CN109476610B (zh) | 一种苯基嘧啶酮化合物的盐、多晶型物及其药物组合物和用途 | |
| CA3145120A1 (en) | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions | |
| WO2019015640A1 (zh) | 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途 | |
| US20080004313A1 (en) | Preparation of crystalline polymorphs of rimonabant hydrochloride | |
| JP2010513394A (ja) | 非ステロイド系グルココルチコイド受容体リガンドとしてのピラゾール誘導体 | |
| EP3960742A1 (en) | Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications | |
| WO2025108293A1 (zh) | 一种双功能气管扩张剂及其结晶和制备方法 | |
| WO2019086008A1 (zh) | 一种苯并三氮唑衍生物的晶型及其制备方法和用途 | |
| TW201139426A (en) | Salts and hydrates of 4-[(3-chlor-4-fluor-phenyl)amino]-6-(cis-4-{n-[(morph-1-olin-4-yl)carbonyl]-n-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | |
| HK1187901A (en) | Phenyl and benzodioxinyl substituted indazole derivatives | |
| HK1154580B (en) | Benzodioxinyl substituted indazole derivatives | |
| HK1243067B (zh) | 氮杂二环式化合物的结晶 | |
| HK1147481B (en) | Polymorphic form | |
| HK1212989B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptro agonist activity | |
| HK1212989A1 (zh) | 具有毒蕈硷受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150629 |